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Point-of-care testing (POCT) is the fastest-growing 
segment of the diagnostic tests used by laboratories 
in the developed world. Laboratories have become 
increasingly involved in supporting testing at the 
bedside in order to improve turnaround time and 
reduce the cost of healthcare delivery.
Measurement of the international normalised ratio (INR) is 
essential in the management of patients on long-term warfarin 
therapy, and POCT has an important role to play in this setting. 
Warfarin has a narrow therapeutic range, and because it is subject 
to numerous drug and food interactions, frequent monitoring to 
maintain the target INR is vital. The target INR is 2.5 (range 2.0 - 
3.0) for most indications, including venous thromboembolic disease, 
non-valvular cardiac conditions including atrial fibrillation, left 
ventricular systolic dysfunction and mural thrombus, and in the first 
3 months following anterior myocardial infarction. The target INR 
is 3.0 (range 2.5 - 3.5) for most patients with mechanical prosthetic 
valves. However, a range of 2.0 - 3.0 is recommended for low-risk 
patients with bileaflet mechanical valves in the aortic position.
Predisposing factors for rheumatic fever persist in developing areas 
of southern Africa, leading to a high incidence of rheumatic valvular 
heart disease. An average of 1 500 patients attend the anticoagulation 
clinic at Charlotte Maxeke Johannesburg Academic Hospital 
(CMJAH), South Africa (SA), every month. Twenty-five percent of 
these are patients with mechanical valve replacements on lifelong 
anticoagulation therapy. In the developing world the question still 
remains whether it is safe to perform mechanical valve replacements 
in patients who will require lifelong anticoagulation therapy and have 
limited or no access to its monitoring. The introduction of POCT in 
peripheral clinics has the potential to solve this problem. There is also 
an opportunity for self-monitoring for patients who are able to test 
themselves at home and avoid taking time off from work to attend a 
clinic for INR testing.
POCT offers other distinct advantages, including improved 
turnaround time for dose adjustments in the clinic setting, a small 
sample volume required for testing and potential long-term cost 
savings. The volume required for analysis is very small (8 μL), making 
this technology particularly suitable for paediatric measurements, as 
blood sampling in this age group is often technically difficult.
Many POC devices are commercially available. The CoaguChek 
XS device (Roche Diagnostics, Switzerland) is a small bench-top 
instrument for INR analysis, suitable for use in anticoagulation 
clinics. This analyser measures the prothrombin time (PT) in seconds 
using an electrochemical method and shows good correlation with 
laboratory automated coagulation analysers up to INR values of 
3.0.[1,2] However, correlation studies at INR values >3.0 are limited.[3-6]
Methods
Study design and population
The study was performed in the main haematology laboratory at the 
CMJAH National Health Laboratory Service (NHLS) over a 3-week 
period. Blood samples were obtained from 304 patients attending the 
anticoagulation clinic at CMJAH. Blood samples for INR analysis were 
obtained by fingerstick testing for measurement on the CoaguChek 
XS and by venepuncture using citrate tubes (Becton-Dickinson, 
UK) for measurement on the STAGO coagulation analysers in 
Validation of the CoaguChek XS international normalised 
ratio point-of-care analyser in patients at Charlotte 
Maxeke Johannesburg Academic Hospital, South Africa
E L Benade, MB BCh; B F Jacobson, MB ChB, MMed (Haem), FRCS (Glasg), FCPath (SA), PhD (Med);  
S Louw, MB BCh, FCPath (SA), MMed (Haem); E Schapkaitz, MB BCh, FCPath (SA), MMed (Haem)
National Health Laboratory Service, Johannesburg, South Africa, and Department of Haematology, Faculty of Health Sciences,  
University of the Witwatersrand, Johannesburg
Corresponding author: E Benade (estee.benade@nhls.ac.za)
Background. Measurement of the international normalised ratio (INR) is essential in the management of patients on long-term warfarin 
therapy. The CoaguChek XS portable coagulometer is a point-of-care test for INR measurement. It offers the advantage of improved patient 
accessibility, particularly in peripheral clinics.
Objectives. To evaluate the clinical utility of the CoaguChek XS for monitoring of patients on standard warfarin therapy (INR 2 - 3) as well 
as those with mechanical heart valve replacements (INR 2.5 - 3.5).
Methods. We compared the performance of the CoaguChek XS device with that of the STAGO laboratory analyser with regard to accuracy 
and precision in 304 patients referred for routine testing.
Results. The mean INR value of the CoaguChek XS of 2.75 (standard deviation (SD) 1.18) was comparable to that of the STAGO (2.65 
(SD 1.04)). The Bland-Altman difference plot revealed good agreement. Bias between the two methods was small, and the imprecision was 
within acceptable limits. Within the target range (2.0 - 3.5), 93.9% of the CoaguChek XS INR readings were within 0.5 units of the standard 
laboratory method result. There was, however, an increase in the variability of the differences between the two test methods when the INR 
was >3.6.
Conclusion. The CoaguChek XS point-of-care device can be used to provide accurate and precise INR measurements over a wide range for 
monitoring of valvular and non-valvular patients on long-term warfarin therapy.
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the laboratory (Fig. 1). Citrate samples of 
adequate volume (>4 mL) received within 2 
hours of collection were included. Samples 
(n=4) processed on the CoaguChek that 
yielded error results were excluded from the 
final analysis.
The study was approved by the University 
of the Witwatersrand Human Research 
Ethics Committee (M130468), and informed 
consent was obtained from the patients.
Study protocol
This validation was performed in acc-
ordance with the International Council for 
Standardisation in Hematology 1993, and 
using the method comparison from the 
Clinical and Laboratory Standards Institute 
(CLSI EP9-A2, USA). For the method 
comparison study, a prospective, side-by-
side comparative study of the CoaguChek 
XS against the STAGO (Roche Diagnostics, 
Switzerland) automated coagulation analyser 
was performed. INR measurement was done 
on 304 adult patient samples. The samples 
were analysed sequentially by a dedicated 
phlebotomist on the CoaguChek XS and by 
a technologist on the STAGO coagulation 
analyser using the respective instruments’ 
standard operating procedures including 
adequate performance of internal quality 
control material (Fig. 1).
For the analysis, whole blood collected by 
capillary sampling was placed on a Coagu-
Chek XS specific test strip. The strips con tain 
recombinant human thrombo plastin with an 
international sensitivity index (ISI) of 1.0. The 
PT was converted to an INR using the ISI 
value. A result is obtained within a minute 
and requires a sample volume of only 8 μL.
Within-run precision evaluation was per-
formed with the normal reference control 
material analysed 20 times. Acceptable 
im precision limits were determined from the 
manufacturer’s within-run precision data.
Warfarin dosage and INR 
measurements
Clinical utility was assessed by two methods. 
Firstly, clinical agreement was measured 
by discrepant INR measurements resulting 
in different warfarin dosage adjustments 
in accordance with the SA guidelines. [7] 
Warfarin dosage adjustments were made 
by dedicated nursing sisters at the anti-
coagulation clinic based on the venous 
plasma laboratory INR method.
Secondly, published criteria for ‘expand-
ed’ and ‘narrow’ clinical agreement were 
also assessed.[2] ‘Expanded’ agreement was 
achieved if the CoaguChek XS and lab-
oratory INR results both fell within one 
of the three different INR ranges, namely 
within, above or below the target range, or 
the difference between the CoaguChek XS 
and laboratory INR when one of the pair was 
within the target range and the other outside 
it was no more than 0.5 INR units.
‘Narrow’ agreement was considered as 
both readings being between 2 and 3, or 
below the target range and within 0.4 INR 
units of each other, or above the target range 
and within 0.8 INR units of each other. If 
one reading was within the target range and 
the other within 0.5 INR units, this was also 
considered to be in ‘narrow’ agreement.[1,5]
Statistical analysis
The results were collated on an Excel 
spread sheet, tabulated and graphically sum-
marised using standard statistical methods. 
Agreement between results obtained on the 
different analysers was evaluated using stan-
dard difference plots.
Results
Study population
Three hundred and four patients partici-
pated in the study. In four cases the Coagu-
Chek XS device failed to produce an INR 
reading, and these samples were exclu ded 
from the analysis (Fig. 1). Patient indications 
for anticoagulation are listed in Table 1.
Method comparison analysis
The limit of agreement between the two 
methods is demonstrated in the Bland-
Altman difference plot (Fig. 2), which 
revealed good agreement. On the logarith-
mic scale, the mean of the differences was 
0.09 (–0.61, 0.79). Sixteen data points were 
outside the 95% limits of agreement. The 
mean INR values of the CoaguChek XS 
and STAGO were 2.75 (standard deviation 
(SD) 1.18) and 2.65 (SD 1.04), respectively, 
representing an overestimation of INR values 
by the CoaguChek XS (Table 2). Below the 
target range (<1.9), 100% of the CoaguChek 
XS INR readings were within 0.5 units of the 
standard laboratory method result. Within 
the target range (2.0 - 3.5), 93.9% of the 
CoaguChek XS INR readings were within 
0.5 units of the standard laboratory method 
result. There was, however, an increase in 
the variability of the differences between the 
two test methods at INR readings above the 
target range (>3.6).
Precision analysis
The intra-assay coefficients of variation were 
within allowable limits of performance in the 
within-target range (0%).
Clinical utility
Clinical agreement was demonstrated by 
93.0% of the values when assessed using 
• Venepuncture for formal INR
  testing using standard
  laboratory method
Patients presenting to
the CMJAH PI clinic for 
INR monitoring and
warfarin dose adjustment
• Patients aged >18 years,
  given information sheet
  in waiting area
• Patients with
  antiphospholipid syndrome
  excluded from study
  • Informed consent obtained
  
Fingerstick INR testing
on two CoaguChek XS
devices by trained
nursing sister
Results tabulated and
compared with laboratory
INR results
• If no reading, patient
  excluded from study (n=4)
  
• Patient’s warfarin dose
  adjusted according to
  laboratory INR study
  
Fig. 1. Flow diagram of patient sample collection. (PI clinic = anticoagulation clinic.)
Table 1. Indications for anticoagulation 
of study patients
Indication for 
anticoagulation n (%)
Thromboembolic events 110 (36.2)
Deep-vein thrombosis 54 (17.8)
Pulmonary embolism 32 (10.5)
 Deep-vein thrombosis and 
pulmonary embolism
13 (4.3)
Upper limb thrombosis 5 (1.6)
Left ventricular thrombus 5 (1.6)
 Dural venous sinus 
thrombosis
1 (0.3)
Valvular heart disease 59 (19.4)
Non-valvular heart disease 87 (28.6)
Dilated cardiomyopathy 5 (1.6)
Congestive cardiac failure 4 (1.3)
Ischaemic heart disease 4 (1.3)
Stroke 3 (0.9)
Congenital cardiac disease 2 (0.7)
Atrial fibrillation 69 (22.7)
Other/not stated 48 (15.8)
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expanded criteria. When using narrow 
agree ment criteria, in the range of 2 - 3.5, the 
laboratory method recorded 181 readings, 
whereas the CoaguChek XS device recorded 
162 (89.5%). At INR values <2, the difference 
between the two readings was <0.4 units in 
70 of the 71 readings (98.6%). The required 
difference of <0.8 units in the INR >3.5 
category was met in 36 of the 45 readings 
(80.0%) (Table 2).
During the study period, 21 of the 300 
CoaguChek XS INR values (7.0%) would 
have been discrepant with standard lab-
oratory INR measurements, resulting in dif-
ferent warfarin dosage adjustments accord-
ing to the SA guidelines.[7,8]
Discussion
In this prospective study, we demonstrated 
the analytical and clinical performance of 
the CoaguChek XS point-of-care device for 
the monitoring of warfarin therapy across a 
wide range of INR values. The CoaguChek 
XS is a portable coagulometer that was 
introduced into the clinical setting in 
October 2005. Previous studies on point-of-
care devices have shown increased variability 
at supratherapeutic INR levels.[2,9,10] A recent 
study performed on the CoaguChek XS, 
however, demonstrated improved accuracy 
even at higher INR values.[11] 
We demonstrated excellent agreement 
between the CoaguChek XS and laboratory 
measurement with the STAGO analyser. 
INR values were overestimated on the 
coagulometer. Ninety-four percent of the 
values had a clinically significant difference 
of <0.5 units in the target range, making 
this an acceptable alternative method for 
monitoring stable patients on long-term 
warfarin therapy with INRs within the 
therapeutic range of 2 - 3. Using narrow 
agreement criteria, the point-of-care device 
also performed well in the INR ranges of 
<2 and 2 - 3.5. However, in the above-target 
range of >3.6, 64.4% were in agreement. 
These findings are consistent with the study 
by Ryan et al.,[12] in which 162 patients 
had dual measurements performed using 
the CoaguChek XS and standard laboratory 
methods. For laboratory INR values of <1.9, 
2 - 3.5 and >3.6, 97.8%, 89.3% and 67% of 
readings, respectively, were within 0.5 INR 
units. In the SA setting, where there is a high 
prevalence of rheumatic heart disease and 
patients with mechanical heart valves, the 
CoaguChek XS point-of-care device could 
be implemented as a method for monitoring 
these patients, but clinical correlation would 
be advised at levels >3.6 units with more 
frequent monitoring and formal laboratory 
testing.
Several research groups have demon-
strated the advantages of having a simple 
and reliable POCT for INR monitoring, 
e.g. small sample volumes and improved 
turnaround time. However, POCT has 
limitations including preanalytical (e.g. staff 
competency) and biological (e.g. temperature 
variations, heparin contamination, extremes 
of haematocrit, fibrinogen levels and 
presence of antiphospholipid antibodies) 
variables. [13- 15]
In SA, the CoaguChek XS point-of-
care device could be implemented in the 
peri pheral clinics as a screening tool for 
patients on long-term warfarin therapy in 
an attempt to reduce the workload of central 
anticoagulation clinics. The capacity and 
infrastructure of peripheral clinics would 
have to be assessed before installation of 
the devices. It is imperative that implemen-
tation of POCT be accompanied by a robust 
quality control system with satisfactory 
performance in internal and external quality 
assessment programmes. In specific settings, 
formal laboratory INR analysis will still  be 
required when INR values >3.6 are obtained 
using this device and there is a history of 
bleeding events.
Conclusion
In this cohort, the CoaguChek XS provided 
accurate and precise INR measurements 
for a wide range (2 - 3.5 units) of INR 
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Fig. 2. Bland-Altman analysis. (95% confidence intervals in blue, bias indicated in black. The dots 
indicate the difference between the CoaguChek and STAGO INR over the mean.)
Table 2. Comparison of CoaguChek XS and laboratory INR results
Parameter CoaguChek XS Laboratory
All INR results, N (%) 300 (100.0)
Mean INR (SD) 2.75 (1.18) 2.65 (1.04)
Mean difference (SD) –0.09 (0.36)
% within 0.5 units 93.0
INR ≤1.9, n (%) 71 (23.7)
Mean INR (SD) 1.61 (0.32) 1.59 (0.30)
Mean difference (SD) –0.03 (0.11)
% within 0.5 units 100.0
INR 2.0 - 3.5, n (%) 184 (61.3)
Mean INR (SD) 2.66 (0.50) 2.61(0.39)
Mean difference (SD) –0.05 (0.28)
% within 0.5 INR units 93.9
INR ≥3.6, n (%) 45 (15.0)
Mean INR (SD) 4.9 (1.3) 4.5 (1.0)
Mean difference (SD) –0.3 (0.7)
% within 0.5 INR units 64.4
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measurements and would be an accurate and reliable method for 
warfarin therapy monitoring.
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